position: EnglishChannel > Sci-Tech News > Article

World's 1st inactivated COVID-19 vaccine produces antibodies

Source: International Communication Center for Science & Technology| 2020-06-23 18:03:41| Author: Qu Jian & China.org

太阳城申博88登入,他强调,总结谋划好改革工作,对做好明年和今后改革工作具有重要意义,要总结经验、完善思路、突出重点,提高改革整体效能,扩大改革受益面,发挥好改革先导性作用,多推有利于增添经济发展动力的改革,多推有利于促进社会公平正义的改革,多推有利于增强人民群众获得感的改革,多推有利于调动广大干部群众积极性的改革。这意味着未来几年内的年均增速将保持在30%左右,这将是产业链上各相关企业发展的大好机会。  有一些新的特点值得提前关注,包括运输需求继续增长、节前客流相互叠加、天气不确定因素较多和安全风险隐患增加。该民调显示,与其他左派候选人相比,前总理瓦尔斯在首轮投票中获得的投票意向遥遥领先。

  根据人社部新闻发言人李忠的介绍,本次国考网上报名人数211.5万人。  号称每小时净化3万立方米空气  无霾之洞是由艺术家丹罗斯加德设计,于9月底进驻北京。要健全完善相关审计制度,让制度管企业、管干部、管资本。河北最多,发布了11条中标信息。


The Phase I/II clinical trials of the world's first inactivated COVID-19 vaccine, developed by Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group (Sinopharm), produced antibodies in every participant, it was announced on Tuesday.

According to a meeting held simultaneously in Beijing and Henan province on Tuesday, the clinical trial results showed that the vaccination was safe without any serious adverse reaction, and after different procedures and different doses of vaccination were adopted, participants in the vaccine group all produced high titers of antibodies. 

People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%.

According to CNBG, the Phase I/II clinical trials were randomized, double-blind, placebo-controlled clinical studies. On April 12, the vaccine obtained the world's first clinical trial approval, and Phase I/II clinical trials were then launched in Wuzhi county of Henan province.

Under the leadership and guidance of the Henan Center for Disease Control and Prevention, the clinical trials were conducted for 66 consecutive days and obtained data on the safety and efficacy of the COVID-19 inactivated vaccine after the administration of the two injections. The data presented research results on different ages, different procedures, different doses, and different injection times in a relatively comprehensive manner. This is also so far the clinical COVID-19 vaccine research that has the longest time span, produces the most comprehensive data and obtains the best research results, thus providing scientific and evaluable data for epidemic prevention and control as well as emergency use.

CNBG said the study was designed to evaluate the safety and immunogenicity of the COVID-19 inactivated vaccine in healthy subjects aged from 18 to 59 for low, medium and high dosages and injections at intervals of 14, 21 and 28 days. 

The study focused on the changes in cellular immunity after vaccination and explored vaccination procedures, immunization dosage, safety, immunogenicity and changes in antibody levels in vivo. Up to now, all the 1,120 subjects that took part in the Phase I/II clinical studies have completed two injections.

For those aged 18 - 59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody positive conversion rate of 97.6%. 

For those who received two medium-dose injections at an interval of 28 days, the neutralizing antibody positive conversion rate reached 100%.

In response to recent new cases in Beijing and the discovery of a new genotype of the virus through whole-genome sequencing, some experts worry that for the new genotype, "the vaccine may weaken or even not work". 

However, Yang Xiaoming, chief scientist of the national "863 Program" vaccine project and chairman of CNBG, told Science and Technology Daily he had noticed the new genotype, but it is "still within the coverage of the vaccine whose Phase I/II unblinding occurred today", so it will not affect the effectiveness of the current inactivated vaccine.

CNBG also said that it is now actively developing overseas cooperation in the Phase III clinical research and has confirmed cooperative intentions with companies and institutions in various countries. It has completed building a high biosafety grade production workshop, which is currently the only COVID-19 vaccine production workshop in the world meeting the requirements of biosafety and GMP standards and capable of meeting the needs of widespread emergency vaccination.

(You can also read it at: 太阳城申博88登入/www_china_org_cn/china/2020-06/22/content_76190287.htm)


Top News

太阳城申博88登入Researchers discover mechanism that makes COVID-19 more severe in diabetics

Brazilian researchers have discovered one of the causes of severe COVID-19 in diabetic patients. Laboratory experiments showed that the higher level of blood sugar in these patients is captured by monocytes, a type of defense cell, and serves as a source of additional energy for the coronavirus to replicate more than in a healthy organism. In response to the increased viral load, the monocytes release large amounts of pro-inflammatory cytokines with several effects including lung cell death.

太阳城申博88登入A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China English

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright ? Science and Technology Daily, All Rights Reserved

mailto: yuhy@太阳城申博88登入 www.yinhe618.com

旧版申博开户直营网 申博官网太阳城娱乐网 申博太阳城在线即时到账 申博会员注册 申博现金网直营 申博亚洲太阳城娱乐直营网
申博太阳城代理开户 申博存款提款直营网 菲律宾太城申博登入 www.687.net www.51tyc.com 申博太阳城官方现金直营网
申博开户平台登入 www.66990.com 太阳城申博娱乐www.sbc66.com 申博太阳娱乐评价 www.88sb.com www.66990.com